



Department of Health and Human Services  
 MaineCare Services, Pharmacy Unit  
 442 Civic Center Drive  
 # 11 State House Station  
 Augusta, Maine 04333-0011  
 Tel: (207) 287-7131; Fax: (207) 287-8601  
 1-866-796-2463  
 TTY: 1-800-423-4331

TO: Maine Drug Utilization Review Board  
 DATE: January 12<sup>th</sup>, 2011  
 RE: Maine DUR Board meeting minutes from January 11, 2011

ATTENDANCE	PRESENT	ABSENT	EXCUSED
Lisa Wendler, Pharm. D., Clinical Pharmacy Specialist, Maine Medical CTR, Chair	X		
Robert Weiss, M.D., Cardiologist, Vice Chair	X		
Amy Enos, Pharm. D. Waltz LTC Pharmacy	X		
John Salvato, M.D., Pediatrician	X		
Laureen Biczak, D.O., Infectious Disease, GHS	X		
Laurie Roscoe, R.Ph., Martin's Point	X		
Lindsay Tweed, M.D., Psychiatrist	X		
Mark Braun, M.D., FACP, Internist/Geriatrician	X		
Mike Coppi, R.Ph.	X		
Mike Ouellette, R.Ph., GHS	X		
Rebecca M. St. Amand, R.Ph., Staff Pharmacist Community Pharmacy - Pittsfield	X		
Timothy Clifford, M.D., Family Practice, GHS	X		
William Alto, M.D. Family Practice, Dartmouth Family Practice Faculty	X		
<b>Non -Voting</b>			
Jennifer Palow, Pharmacy Manager, OMS	X		
Dora Mills MD, Medical Director, OMS	X		

Guests of the board: Dr. Jeff Barkin, Rod Prior MD

---

CALL TO ORDER: 6PM

---

**OLD BUSINESS**

---



---

DUR MINUTES FROM JANUARY

---

November minutes were approved

*Caring..Responsive..Well-Managed.. We are DHHS.*

---

## PUBLIC COMMENTS

---

- David Day spoke as a representative of Boehringer Ingelheim and gave information to the board on the economic value of Pradaxa in stroke risk reduction in non-valvular atrial fibrillation. He also handed out a leaflet with information.
  - Dr Clifford was concerned about antidotes for patients having major bleeds. None exist. Will have modeling done to see if true MaineCare Medicaid net costs corroborate pharmacoeconomic savings reported in recent studies.
  - Dr Weiss wants to revisit this he would like to compare acquisition cost to discounts given by the hospitals
- Dipak Mistry a Medical Liason for BMS gave information to the board on Sprycel and asked that it be preferred on the ME PDL. He stated that the FDA has approved this med as a first line medication for Chronic Myloid Leukemia (CML). Emphasized once a day dosing and non-dependancy with regards to meals.
- Pat Harvey representing Sunovion Pharmaceuticals gave information to the board on Latuda and trials done with placebos. Indicated that dose related adverse events include somnolence. He would like to see this listed as a first line agent on our ME PDL.
  - Dr. Weiss stated that they were not interested in placebo trials that were brought up and would like to see more clinical trials with actual comparators.
- Kristy Owen representing Novartis gave information on Gilenya, she had previously spoken at length with GHS about the clinical trials and data that had been collected so kept this brief. Spoke of 54% reduction in relapses and decrease in T2 lesions.
- David Moltz, MD from the Psych workgroup gave a handout with questions and answers from a previous DUR session referring to Suboxone prescribing and diversion. He stated that use of a bubble pack would decrease opioid diversion.
  - Dr. Clifford asked who would supply the bubble package to pharmacies? Dr. Moltz replied that currently the Addiction Resource Center (ARC) does use the bubble packs and he also stated that Medical Center Pharmacy and Wilsons drug offer bubble packing for a \$1.00 fee.
  - Dr. Barkin asked if there was any resistance by other MD's regarding the bubble packs and the response was that there was none at this time, most agree with this approach.
  - Mike Ouellette asked how many Pharmacies were involved with dispensing this way and the response was between 30-40
- Vince Lawlor representing Merck asked if there was any further discussion regarding the National guidelines for Diabetes.
  - Dr. Clifford responded that there would be further discussion in the February DUR meeting.
- Dr. Tracy Shilling, a neurologist from Waterville had questions on the PA requirements on Ampyra, her concern was with the 4-week follow-up requirement. She felt that it was not acceptable based on

the office schedule being as busy as it is. She felt that an 8-week follow-up would be more acceptable to most office schedules.

- Dr. Biczak noted that it has already been updated to reflect a 12-week check.
- Morrie Olson representing Alkermes Pharmaceuticals gave information regarding Vivitrol and the new indication for the treatment of Opioid dependency. Indicated that 30 day injection was less likely to have compliance issues as seen with oral daily tablets.

---

#### STATIN INTERVENTION UPDATE

---

- There was discussion about the survey form and the information that needs to be entered. The consensus was that the survey was boring and the pertinent information wasn't asked for until the end of the survey. The survey will be reworked to be more precise in requested information. Mike Ouellette and Dr. Weiss along with collaboration from Dr. Braun will work on getting this completed.

---

#### PSYCH WORK GROUP MONTHLY UPDATE

---

- Dr. Barkin noted that he has received about 600 Antipsychotic Adherence reports back from providers.
  - $\frac{3}{4}$  of the responses were that the member has moved or wasn't their patient
  - $\frac{1}{4}$  stated adverse affects
- Dr. Barkin also stated that 15% of the MD's found this information helpful.
- Dr. Clifford said that Dr. Alex Atayev is creating a report with the stats from the information that has been gathered to see if the adherence reporting intervention is having any affect on compliance.

## NEW BUSINESS

---

---

---

#### PDL / PA CRITERIA

---

New Drugs: Members reviewed individual drug monographs.

- Alsuma- will be a non-covered drug
- Benzefoam- will be non-preferred
- Beyaz\_ will be non-preferred
- Bromday- will be non-preferred
- Butrans- will be non-preferred
- Gilenya- voted to re-visit in October
- Glassia- will be non-preferred

- Kapvay- will be non-preferred
- Lastacaft- will be non-preferred
- Latuda- will be non-preferred
- Lodosyn- will be non-preferred
- Natazia- will be non-preferred
- Ozurdex- will be non-preferred
- Pradaxa- will re-visit in October
- Suboxone film- preferred will also re-visit bubble packing
- Tekamlo- will be non-preferred
- Veltin- will be non-preferred
- Zencia wash- will be non-preferred
- Zuplenz- will be non-preferred
- Vivitrol new indication- will be non-preferred

All of the above medications were approved with abstentions on all drugs by Dr. Weiss.

---

ADJOURNMENT: 8PM

---

The next meeting is February 8<sup>th</sup> 6:00-8:00 pm.